Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04760860
Other study ID # 202101470
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date October 2024
Est. completion date December 2026

Study information

Verified date May 2024
Source University of Iowa
Contact qiang zhang, MD
Phone 4154251369
Email qiang-zhang@uiowa.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The TZ-DLB trial will be a 3:2 (active:placebo) randomized, double-blind, placebo-controlled Pilot trial to evaluate the tolerability of terazosin for the treatment of dementia with Lewy bodies.


Description:

This will be a single center, randomized, double-blind, placebo-controlled, pilot study to assess the tolerability of terazosin (TZ) at 1 and 5 milligrams (MG) daily for patients with DLB. The primary goal of this study is to assess the tolerability of TZ in patients with DLB. This is a pilot study and is not powered to assess efficacy of this medication. Our hope is that this study will guide future studies of this (and similar) medications for the disease modification of DLB. This study is also aimed to learn more about how patients with produce and use energy and if TZ can help to reverse energy deficits that appear in DLB.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date December 2026
Est. primary completion date October 2026
Accepts healthy volunteers No
Gender All
Age group 0 Years to 90 Years
Eligibility Inclusion Criteria: - Men or women with the diagnosis of dementia with Lewy Bodies per 2017 DLB Consortium criteria. - Baseline MOCA 18 or above. On stable AChEI and/or memantine treatment regimen for =4 weeks prior to baseline. Exclusion Criteria: - Subjects unwilling or unable to give informed consent - No confounding acute or unstable medical, psychiatric, orthopedic condition. Subjects who have hypertension, diabetes mellitus, depression, or other common age-related illness will be included if their disease under control with stable treatment regimen for at least 30 days. - Orthostatic hypotension defined as symptomatic decrease in BP > 20mmHg systolic or > 10mmHg diastolic on supine to sitting or standing, or a sitting blood pressure of =90/60. - Clinically significant traumatic brain injury or post-traumatic stress disorder - Presence of other known medical comorbidities that in the investigator's opinion would compromise participation in the study - Psychiatric comorbidities including major depression, bipolar affective disorder, or other mental health disorders that are sufficiently severe to increase adverse event risk or impact neurology assessment in the opinion of the responsible site principal investigator. Subjects with clinically significant depression as determined by a Beck Depression Inventory score greater than 21 at the screening visit. Current suicidal ideation within one year prior to the baseline visit as evidenced by answering "yes" to Questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale (C-SSRS) If the participant has a Beck Anxiety Score greater than 22 at the initial screening visit. - Use of investigational drugs within 30 days before screening - Subjects have to be on a stable regimen of central nervous system acting medications (benzodiazepines, antidepressants, hypnotics) for 30 days prior to the baseline visit - Use of doxazosin, alfuzosin, prazosin, or tamsulosin - For female participant, pregnancy, or plans for child-bearing during study period - Participant is restricted from traveling to and from the study site

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Terazosin Hydrochloride
In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the Terazosin group will receive Terazosin hydrochloride treatment for 15 weeks. Participants will start at 1mg daily for the first 6 week, then the dosage will be increased to 5mg daily over 3 weeks, and continued for the last 6 weeks.
Other:
Placebo
In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the control group will receive placebo for 15 weeks.

Locations

Country Name City State
United States University of Iowa Iowa City Iowa

Sponsors (1)

Lead Sponsor Collaborator
Qiang Zhang

Country where clinical trial is conducted

United States, 

References & Publications (2)

Cai R, Zhang Y, Simmering JE, Schultz JL, Li Y, Fernandez-Carasa I, Consiglio A, Raya A, Polgreen PM, Narayanan NS, Yuan Y, Chen Z, Su W, Han Y, Zhao C, Gao L, Ji X, Welsh MJ, Liu L. Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. J Clin Invest. 2019 Oct 1;129(10):4539-4549. doi: 10.1172/JCI129987. — View Citation

Simmering JE, Welsh MJ, Liu L, Narayanan NS, Pottegard A. Association of Glycolysis-Enhancing alpha-1 Blockers With Risk of Developing Parkinson Disease. JAMA Neurol. 2021 Apr 1;78(4):407-413. doi: 10.1001/jamaneurol.2020.5157. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of intervention-related adverse events between treatment arms All patient-reported adverse events will be compared. 15 weeks
Primary Frequency of drop-out/discontinuation of study intervention for any reason The number of participants in each group who drop out of the study for any reason will be compared. 15 weeks
Primary Brain [ATP] as measured by 31P-Magnetic Resonance Spectroscopy Brain [ATP] as measured by 31P-Magnetic Resonance Spectroscopy at baseline, 6 weeks and 15 weeks
Secondary To assess the mean change in systolic and diastolic blood pressures Blood pressure will be evaluated at baseline, 2 weeks, 6 weeks and 12 weeks at baseline, 6 weeks and 15 weeks
Secondary Unified Parkinson Disease Rating Scale (UPDRS) part III Motor examination Unified Parkinson Disease Rating Scale (UPDRS) part III will be evaluated at baseline, 2 weeks, 6 weeks and 12 weeks at baseline, 6 weeks and 15 weeks
Secondary Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) will be evaluated at baseline and 12 weeks at baseline, 6 weeks and 15 weeks
Secondary Montreal Cognitive Assessment Montreal Cognitive Assessment at baseline, 6 weeks and 15 weeks
Secondary The Clinician Interview-Based Impression of Change, plus carer interview (CIBIC-Plus) CIBIC-Plus will be evaluated at baseline and at 12 weeks at baseline, 6 weeks and 15 weeks
Secondary Neuropsychiatric inventory NPI will be evaluated at baseline and at 12 weeks at baseline, 6 weeks and 15 weeks
Secondary Fluorodeoxyglucose (FDG)-positron emission tomography (PET) A surrogate for glucose metabolism in the brain at baseline, 6 weeks and 15 weeks
Secondary Serum ATP levels Serum ATP level changes will be compared between the TZ and the placebo arms at baseline, 6 weeks and 15 weeks
Secondary Serum TeraZosin levels Serum Terazosin levels will be analyzed and a correlation between ATP levels and TZ levels will be evaluated at baseline, 6 weeks and 15 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT03996460 - K0706 for Patients Diagnosed With Dementia With Lewy Bodies Phase 2
Recruiting NCT04335994 - ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing N/A
Recruiting NCT02194816 - Modifiable Variables in Parkinsonism (MVP)
Active, not recruiting NCT01208675 - The Swedish BioFINDER Study
Completed NCT03538522 - A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831 Phase 2
Recruiting NCT03672448 - The China Longitudinal Aging Study of Cognitive Impairment
Completed NCT01340001 - Effects of Nucleus Basalis of Meynert Stimulation on Cognitive Disorders in Dementia With Lewy Bodies N/A
Terminated NCT02928445 - Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension Phase 2/Phase 3
Completed NCT02910102 - Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia Phase 2
Terminated NCT02871427 - Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder Phase 2
Completed NCT05188105 - Alpha tACS in Dementia With Lewy Bodies N/A
Active, not recruiting NCT04167813 - Trial of Ondansetron as a Parkinson's HAllucinations Treatment Phase 2
Enrolling by invitation NCT04954183 - Development of an EEG Diagnostic for Alzheimer's Disease
Recruiting NCT05326750 - Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases N/A
Completed NCT01023672 - "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies" Phase 4
Completed NCT03907748 - Home-based Family Caregiver-delivered Music and Reading Interventions for People With Dementia N/A
Completed NCT04649164 - Learning to PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia N/A
Recruiting NCT03924414 - Trial of Parkinson's And Zoledronic Acid Phase 4
Completed NCT05885620 - SAMi Intervention Study to Evaluate Smartwatch Interventions in Persons With MCI and Dementia N/A
Not yet recruiting NCT04555629 - Advanced Cognitive Stimulation Therapy Hong Kong (ACST-HK) N/A